Opendata, web and dolomites

PromoTeRapy SIGNED

Haploinsufficiency and Intractable Epilepsy Rescue Increasing Endogenous Gene PromoterEfficiency

Total Cost €


EC-Contrib. €






 PromoTeRapy project word cloud

Explore the words cloud of the PromoTeRapy project. It provides you a very rough idea of what is the project "PromoTeRapy" about.

syndrome    biophysics    opportunity    full    health    molecular    clinical    reprogramming    collaborators    genetics    excitatory    genetically    underlies    epilepsy    panoply    model    haploinsufficiency    neurosciences    crispr    promoters    risks    sodium    nav1    fibroblasts    disorders    scn1a    exploits    models    tools    focal    regulate    insights    endogenous    kv1    genes    epileptic    therapy    leads    treat    sequences    epilepsies    treatment    severe    splice    genetic    resource    channel    network    mouse    rescue    tool    combine    unparalleled    therapeutic    gene    intractable    exogenous    encodes    mutagenesis    insertional    variants    expertise    functional    regulatory    patients    biology    untranslated    burdens    create    excitability    neurophysiology    neurology    interneurons    multidisciplinary    integrating    haploinsufficency    mechanistic    techniques    first    international    ucl    neurons    dravet    strategy    neuronal    knca1    fibroblast    expression    genome   

Project "PromoTeRapy" data sheet

The following table provides information about the project.


Organization address
city: London
postcode: WC1E 6BT

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 195˙454 €
 EC max contribution 195˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2018-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (London) coordinator 195˙454.00


 Project objective

This proposal will develop a new tool to rescue haploinsufficiency, which underlies many genetic disorders of neuronal excitability, and provide a new approach to treatment of intractable epilepsy. This new tool is based on the CRISPR-On technology which can regulate the expression of endogenous genes by directly targeting their promoters, which allows expression of the full panoply of splice variants and untranslated regulatory sequences. Importantly, the method does not require integrating exogenous genes into the genome, which has potential risks of insertional mutagenesis. Haploinsufficency of SCN1A, which encodes the sodium channel Nav1.1, leads to Dravet Syndrome, a severe epilepsy. My first aim is to increase SCN1A gene expression in interneurons derived by reprogramming fibroblasts obtained from Dravet Syndrome patients. I will then determine whether this strategy can be effective in non-genetic epilepsies by applying CRISPR-On technology to increase KNCA1(Kv1.1) expression in excitatory neurons in a mouse model of focal epilepsy. This project will combine my previous experience with functional analysis of neurons in different epileptic models; an unparalleled resource of genetically-characterized patients, a well characterized model of intractable epilepsy, and gene therapy techniques at the UCL Institute of Neurology; and expertise on the CRISPR-On method and fibroblast reprogramming of international collaborators. Epilepsy is one of the most important health burdens within the clinical neurosciences, and finding tools that open new mechanistic and therapeutic insights is a high priority. My proposal exploits an opportunity to establish a new tool to treat epileptic disorders and to create an international multidisciplinary network including neurophysiology, clinical neurology, molecular biology, biophysics and genetics.


year authors and title journal last update
List of publications.
2017 Gareth Morris, Marco Leite, Dimitri M. Kullmann, Ivan Pavlov, Stephanie Schorge, Gabriele Lignani
Activity Clamp Provides Insights into Paradoxical Effects of the Anti-Seizure Drug Carbamazepine
published pages: 5484-5495, ISSN: 0270-6474, DOI: 10.1523/JNEUROSCI.3697-16.2017
The Journal of Neuroscience 37/22 2019-06-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROMOTERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROMOTERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

DiMaS (2019)

Retrospective genomic analyses of shortfin Mako shark (Isurus oxyrinchus) using DNA from archived jaws

Read More